JNJ Dividend 2026: Quarterly Payout, 60-Year King Streak, History & Is It Safe?
Johnson & Johnson (NYSE: JNJ) is one of the most celebrated dividend stocks in history — a Dividend King with more than 63 consecutive years of annual dividend increases. Its current quarterly dividend of $1.30 per share delivers an estimated annualized payout of $5.20 per share and a trailing yield of approximately 2.2%–2.5% at early 2026 share prices.
Unlike many high-yield dividend stocks, JNJ is not primarily owned for its yield — it is owned for its extraordinary reliability. In more than six decades of paying and increasing dividends, Johnson & Johnson has never cut its payout. It survived oil crises, recessions, the dot-com collapse, the 2008 financial crisis, COVID-19, and the 2023 Kenvue consumer health spinoff with its dividend streak and King status intact.
This guide covers JNJ's complete 2026 dividend profile: current payout details, full dividend history, the Kenvue spinoff context, payout sustainability analysis, ex-dividend dates, a peer comparison with leading blue-chip dividend stocks, and a framework for evaluating whether JNJ belongs in your income portfolio.
JNJ Dividend Snapshot (Current Data)
The table below summarizes Johnson & Johnson's current dividend profile as of early 2026. Verify live data directly at investor.jnj.com or your brokerage.
| Metric | Current Value | Notes |
|---|---|---|
| Quarterly Dividend Per Share | $1.30 | Increased from $1.24 in Q2 2025 |
| Annual Dividend Per Share (est.) | ~$5.20 | Based on $1.30 × 4 quarters |
| Trailing Dividend Yield (TTM) | ~2.2%–2.5% | Varies with share price; verify current |
| Payment Frequency | Quarterly | Mar, Jun, Sep, Dec payment months |
| Stock Ticker & Exchange | JNJ — NYSE | Johnson & Johnson |
| Company Type | Healthcare Conglomerate | Pharma + MedTech; consumer health spun off (Kenvue, 2023) |
| Market Cap (est.) | ~$350–400 billion | One of the largest U.S. healthcare companies |
| Payout Ratio (EPS-based, est.) | ~46%–53% | Conservative for a mega-cap; leaves growth headroom |
| Consecutive Years of Dividend Increases | 63+ years | As of 2025; qualifies as a Dividend King (>50 years) |
| Dividend King Status | Yes ✅ | Also remained on the Dividend Aristocrats Index |
All figures are approximate based on publicly available data as of early 2026. Verify current dividend amounts, yields, and payout ratios at investor.jnj.com or your brokerage.
About Johnson & Johnson as a Dividend Stock
Johnson & Johnson was founded in 1886 and has been publicly listed for decades. Following the 2023 Kenvue spinoff of its consumer health segment (Band-Aid, Neutrogena, Tylenol), J&J now operates through two primary business segments:
- Innovative Medicine (Pharmaceuticals): Patented drugs including oncology, immunology, cardiovascular, and neuroscience therapies. This segment generates J&J's highest margins and represents the largest share of revenue and earnings. Key products include Darzalex (multiple myeloma), Stelara (immunology), and Tremfya.
- MedTech: Medical devices, surgical instruments, and orthopedic products for hospitals and healthcare systems. Lower margins than pharma but significant scale and recurring demand from procedural volumes.
J&J's business model is defensively positioned: it sells products that hospitals, doctors, and patients need regardless of economic cycles. Healthcare demand is largely recession-resistant, which is why JNJ's dividend has survived every major downturn of the past six decades. For a broader view of where JNJ fits in a dividend portfolio, see our highest dividend yield stocks guide.
What Is a Dividend King? JNJ's Streak Explained
Johnson & Johnson is classified as both a Dividend Aristocrat and a Dividend King — two related but distinct designations that reflect the length of its consecutive annual dividend increase streak.
Dividend Aristocrat vs. Dividend King
| Designation | Requirement | JNJ Qualifies? | Notes |
|---|---|---|---|
| Dividend Aristocrat | S&P 500 member + 25+ consecutive years of increases | Yes ✅ | JNJ has 63+ years — far exceeds the 25-year threshold |
| Dividend King | 50+ consecutive years of dividend increases | Yes ✅ | One of fewer than ~55 U.S. companies with King status |
JNJ's 63+ year streak is remarkable because it represents a track record of raising dividends through every major economic disruption of the modern era: the 1970s stagflation and oil embargo, Black Monday (1987), the S&L crisis, the dot-com bust, the 2008–2009 financial crisis, the 2020 COVID crash, rising interest rates in 2022–2023, and the organizational complexity of spinning off Kenvue in 2023. Each year, Johnson & Johnson's board has declared a higher dividend — a testament to the durability of the business model.
For the complete current list of Dividend Aristocrats and how the index works, see our Dividend Aristocrats guide.
JNJ Dividend History (2018–2026)
The table below shows JNJ's quarterly dividend amounts and key context for each year. Although JNJ has been increasing dividends since the early 1960s, the table focuses on the most investor-relevant recent period.
| Year | Starting Quarterly Div | Annual Div (approx.) | Annual Increase % | Key Events |
|---|---|---|---|---|
| 2018 | $0.84 | ~$3.54 | ~7% | Strong pharma growth; Actelion integration |
| 2019 | $0.90 | ~$3.75 | ~6% | Dividend increased; talc litigation concerns begin |
| 2020 | $1.01 | ~$4.04 | ~7.7% | COVID; elective procedure impact on MedTech; no dividend impact |
| 2021 | $1.06 | ~$4.24 | ~5% | Recovery; COVID vaccine revenue; dividend raised |
| 2022 | $1.13 | ~$4.52 | ~6.6% | Strong Innovative Medicine growth; Kenvue spinoff announced |
| 2023 | $1.19 | ~$4.78 | ~5.3% | Kenvue IPO & spinoff completed; dividend streak maintained post-spinoff |
| 2024 | $1.19 → $1.24 | ~$4.91 | ~2.7% | Increased Q2, held at $1.24 Q3–Q4; Stelara biosimilar headwinds |
| 2025 | $1.24 → $1.30 | ~$5.14 | ~4.7% | Increased to $1.30 from Q2; 63rd consecutive annual dividend increase |
Annual dividend figures are approximated from quarterly rates. Percentage increases are calculated year-over-year on an annual basis. Verify the complete official dividend history at investor.jnj.com.
What the table illustrates is not just consistency — it is consistent growth. JNJ has raised its annual dividend at an average rate of approximately 5%–7% per year over the past decade, compounding income for long-term holders. At a 5% average annual growth rate, a $1,000 annual dividend income from JNJ today would grow to approximately $1,629 in 10 years, purely from dividend increases (excluding reinvestment and share price changes).
The 2023 Kenvue Spinoff: What It Means for Dividends
In 2023, Johnson & Johnson completed the separation of its consumer health business — the segment behind Band-Aid, Neutrogena, Tylenol, Listerine, and Aveeno — into an independent publicly traded company called Kenvue (NYSE: KVUE). This was the most significant structural change to J&J in decades.
How the Spinoff Worked
Kenvue's IPO occurred in May 2023, raising approximately $3.8 billion. J&J then completed the separation through a share exchange offer in August 2023, in which JNJ shareholders could exchange their JNJ shares for Kenvue shares, or simply retain their JNJ shares and receive a pro-rata distribution of the remaining Kenvue shares J&J held.
Did the Kenvue Spinoff Affect JNJ's Dividend?
No — JNJ's dividend streak was fully maintained. Shortly after completing the Kenvue separation, J&J confirmed it would maintain its quarterly dividend at $1.19 per share, preserving its unbroken dividend increase history. The dividend King designation was not affected.
This is meaningfully different from AT&T's WBD spinoff, which required a 46% dividend cut. J&J's consumer segment generated a relatively smaller share of total group earnings compared to AT&T's media contribution, and J&J's remaining two-segment business (pharma + MedTech) retained sufficient earnings power to support the existing dividend trajectory.
JNJ Ex-Dividend Dates & Payment Schedule 2026
JNJ pays quarterly dividends in March, June, September, and December. The table below shows the 2025 dates based on publicly available information — always confirm exact dates at investor.jnj.com or your brokerage.
| Quarter | Quarterly Amount | Ex-Dividend Date | Pay Date |
|---|---|---|---|
| Q1 2025 | $1.24 | February 18, 2025 | March 4, 2025 |
| Q2 2025 | $1.30 | May 27, 2025 | June 10, 2025 |
| Q3 2025 | $1.30 | August 26, 2025 | September 9, 2025 |
| Q4 2025 | $1.30 | November 25, 2025 | December 9, 2025 |
Dates reflect J&J's announced 2025 schedule based on publicly declared quarterly dividends. Always verify the precise ex-dividend date, record date, and payment date at investor.jnj.com before purchasing shares.
How to Qualify for a JNJ Dividend Payment
To receive any quarterly JNJ dividend, you must purchase and hold shares before the ex-dividend date. Purchasing on or after the ex-date means you are not entitled to that quarter's dividend. JNJ offers a Dividend Reinvestment Plan (DRIP) through Computershare, allowing shareholders to automatically reinvest dividends into additional JNJ shares at no commission.
Is JNJ's Dividend Sustainable? Payout Ratio Analysis
For most large-cap non-REIT stocks like JNJ, the earnings-based payout ratio (dividends paid ÷ reported EPS) is the primary sustainability metric. JNJ's long-term payout ratio has typically ranged between 40%–55%, which is conservative for a blue-chip healthcare company.
Current Payout Ratio Math
- Estimated annual dividend: ~$5.20/share ($1.30 × 4)
- Adjusted EPS (est., 2025): ~$10.00–$11.00 per share (management guidance range; verify latest)
- Implied payout ratio: ~47%–52%
A payout ratio below 60% for a large-cap healthcare company with stable, recurring revenues generally indicates a dividend that is well-covered by current earnings, with meaningful retained earnings available for R&D, acquisitions, and debt management.
What Threatens the Payout Ratio?
The key risks to JNJ's payout ratio are pharmaceutical patent cliffs and litigation costs. Stelara (ustekinumab) — which was one of JNJ's largest revenue contributors — faces biosimilar competition beginning in 2025. If Stelara revenue declines rapidly and is not replaced by the next generation of drugs (Darzalex, Tremfya, Rybrevant), adjusted EPS could compress, pushing the payout ratio higher.
However, J&J has historically demonstrated an ability to navigate patent cliffs through pipeline depth. The company consistently invests 15%+ of revenue in R&D, maintaining a robust clinical pipeline that has historically replaced revenue from patent-expired drugs over multi-year cycles.
JNJ vs. PG vs. MMM vs. ABT: Dividend Peer Comparison
Income investors considering JNJ should compare it to other large-cap blue-chip dividend payers with long growth streaks. The table below benchmarks JNJ against Procter & Gamble (PG), 3M (MMM), and Abbott Laboratories (ABT):
| Company | Ticker | Annual Div (est.) | Yield (approx.) | Consecutive Increases | King or Aristocrat? | 5-Yr Div. CAGR |
|---|---|---|---|---|---|---|
| Johnson & Johnson | JNJ | ~$5.20 | ~2.3% | 63+ years | King ✅ & Aristocrat ✅ | ~5%–6% |
| Procter & Gamble | PG | ~$3.94 | ~2.3%–2.5% | 68+ years | King ✅ & Aristocrat ✅ | ~5%–6% |
| 3M Company | MMM | ~$2.80 | ~2.0% | ~65 years (cut in 2024) | Removed (cut 2024) ❌ | Negative (cut) |
| Abbott Laboratories | ABT | ~$2.36 | ~1.7%–1.9% | 53+ years | King ✅ & Aristocrat ✅ | ~7%–8% |
All figures are approximate as of early 2026. Verify current dividends and streaks at each company's investor relations page. Past dividend growth rates are not predictive of future increases.
JNJ vs. PG: Both are Dividend Kings with similar yields (~2.3%) and similar 5-year growth rates. PG is slightly older in streak (68 vs. 63 years) and is in consumer staples rather than healthcare. For investors who prefer non-healthcare exposure, PG is a direct comparator; for pharma/MedTech exposure, JNJ is preferred.
JNJ vs. MMM: 3M was a long-standing Dividend King but cut its dividend in 2024 as part of spinning off its healthcare segment. This illustrates that even multi-decade King status does not guarantee permanent safety — business model disruption can force a reset.
JNJ vs. ABT: Abbott offers a higher 5-year dividend growth rate (~7–8% CAGR) and is also a Dividend King. ABT's lower current yield (1.7–1.9%) reflects its higher share price appreciation component. JNJ offers more current income; ABT offers faster dividend compounding.
For broader context on dividend-focused investing, see our Dividend Aristocrats list and guide and our top dividend stocks to watch in 2025.
How to Evaluate JNJ for Your Portfolio
JNJ is a core holding in many institutional income portfolios. Use this framework to assess whether it fits your specific situation:
1. Clarify Your Goal: Are You Buying JNJ for Income or Total Return?
JNJ's ~2.3% yield is below average compared to many dividend stocks. If your primary goal is maximum current income, higher-yield stocks or dividend ETFs may be more effective. JNJ's core case is reliable income growth — a 5% annual dividend increase compounds favorably over 10–20 years. Investors with a long time horizon benefit most from JNJ's compounding dividend trajectory.
2. Monitor the R&D Pipeline and Patent Cliff Exposure
JNJ's ability to raise its dividend depends on its ability to replenish earnings as key drugs lose patent protection (notably Stelara beginning 2025). Track quarterly earnings releases for adjusted EPS guidance, new drug approvals from the FDA, and clinical trial results in oncology and immunology — these are the leading indicators of JNJ's future dividend growth capacity.
3. Watch the Litigation Liability
JNJ faces ongoing litigation related to talc-based baby powder and alleged links to ovarian cancer. The company has reported settling claims and restructuring the liability through a bankruptcy subsidiary — but the full resolution timeline and financial impact remain uncertain. While existing reserves appear adequate for current settlement trajectories, a major adverse legal judgment could materially affect earnings and capital allocation priorities.
4. Tax Efficiency — Qualified Dividends
JNJ's quarterly dividends qualify as qualified dividends for most U.S. individual investors holding shares for the required holding period (60+ days surrounding the ex-dividend date). Qualified dividends are taxed at 0%, 15%, or 20% capital gains rates rather than ordinary income rates — making JNJ more tax-efficient in a taxable brokerage account than bonds or REITs. For our full explanation of dividend taxation, see our guide to dividends and how they work.
5. Consider JNJ as Portfolio Defense
During the 2020 COVID crash and the 2022 high-inflation bear market, JNJ significantly outperformed the broader market on a relative drawdown basis. For investors using dividend stocks as portfolio stabilizers, JNJ's low beta and defensive healthcare revenues make it a useful counterweight to more cyclical portfolio components.
Risks & Downsides of Owning JNJ for Dividends
JNJ's dividend record is exceptional, but no stock is risk-free. Key risks for income investors:
- Low current yield (~2.3%): JNJ's yield is relatively modest compared to telecom or REIT dividend payers. Investors who need maximum income now may be underserved by a 2.3% yield — other options exist at 4–8% yield with varying risk profiles. See our highest dividend yield stocks guide for alternatives.
- Pharmaceutical patent cliffs: Stelara (biosimilars entering 2025) represents meaningful revenue exposure. If new drug revenues (Darzalex, Tremfya, pipeline entrants) do not offset Stelara losses adequately, adjusted EPS could decline — constraining the payout ratio and potentially slowing future dividend increases.
- Talc litigation uncertainty: JNJ has been managing legal liability related to talc-based products for several years. While the company has established substantial legal reserves, the eventual settlement or judgment scale remains uncertain. A materially larger-than-expected resolution could redirect cash from dividends and buybacks.
- Slow share price appreciation: JNJ's stock has generally lagged growth-oriented healthcare companies (biotech, innovative devices) over 3–5 year periods. Income investors who ignore total return may find their portfolio underperforming index benchmarks despite steady dividend income.
- Acquisitions adding debt or integration risk: JNJ regularly uses acquisitions to replenish its pipeline (e.g., Shockwave Medical in 2024 for ~$13.1 billion). Large acquisitions increase leverage and may temporarily divert capital from dividend increases or share buybacks.
- Healthcare regulatory risk: Drug pricing regulation, FDA approval decisions, and changes to Medicare/Medicaid reimbursements can materially affect JNJ's pharma revenue. U.S. drug pricing policy risk remains an ongoing structural headwind.
Summary & Key Takeaways
- ✅ JNJ pays $1.30 per share quarterly (~$5.20 annualized), yielding approximately 2.2%–2.5% — paid in March, June, September, and December.
- ✅ Johnson & Johnson is a Dividend King with 63+ consecutive years of annual dividend increases — one of the longest streaks on record and well above the 50-year King threshold.
- ✅ JNJ maintained its dividend intact through the 2023 Kenvue consumer health spinoff — no cut, no freeze — distinguishing it from spinoff-driven cuts like AT&T's 2022 reduction.
- ✅ The EPS payout ratio of ~46%–53% is conservative for a mega-cap healthcare company, providing headroom for continued annual increases even in moderate earnings growth environments.
- ✅ JNJ's dividends are classified as qualified dividends — taxed at preferential capital gains rates in taxable accounts, improving after-tax yield efficiency.
- ⚠️ Current yield (~2.3%) is below many income stocks — JNJ is better suited for dividend growth investors than those seeking maximum current income.
- ⚠️ Stelara patent expiry and biosimilar competition (beginning 2025) represents a meaningful near-term EPS headwind — monitor quarterly adjusted EPS guidance to assess dividend growth trajectory.
- ⚠️ Talc litigation liability remains a variable financial risk that could affect capital allocation, though existing reserves appear substantial.
- ⚠️ Large acquisitions (e.g., Shockwave Medical, ~$13.1B) add leverage temporarily — watch net debt trajectory relative to earnings for signs of dividend growth constraint.
Frequently Asked Questions
Johnson & Johnson currently pays $1.30 per share per quarter, equating to approximately $5.20 per share annually. This rate has been in effect since Q2 2025, when J&J increased from $1.24 to $1.30. At share prices in the $155–$165 range (approximate as of early 2026), this generates a trailing yield of roughly 2.2%–2.5%. Always verify the current declared quarterly dividend at investor.jnj.com, as dividend amounts are confirmed quarterly by J&J's Board of Directors.
Johnson & Johnson has raised its dividend for more than 63 consecutive years as of 2025. This streak began in the early 1960s and has continued through every major economic cycle since — including the 2008 financial crisis, the COVID-19 pandemic, and the 2023 Kenvue spinoff. This qualifies JNJ as both a Dividend Aristocrat (25+ years of increases) and a Dividend King (50+ years of increases). Fewer than approximately 55 U.S. publicly traded companies hold Dividend King status.
No — JNJ's dividend was fully maintained after the Kenvue spinoff. When J&J completed the separation of its consumer health segment (Kenvue, NYSE: KVUE) in 2023, the company confirmed it would continue its $1.19/quarter dividend without interruption. Unlike AT&T's 2022 dividend cut following its media spinoff, J&J's remaining pharma and MedTech businesses retained sufficient earnings power to support the existing dividend. The Kenvue separation did not break JNJ's decades-long dividend increase streak, and J&J subsequently raised the dividend in 2024 and 2025.
JNJ pays dividends quarterly, with ex-dividend dates typically occurring in February, May, August, and November. For 2025, the known ex-dates were: Q1 — February 18; Q2 — May 27; Q3 — August 26; Q4 — November 25. Always verify the precise upcoming ex-dividend date at investor.jnj.com or your brokerage's dividend calendar before purchasing shares. You must buy JNJ shares before the ex-dividend date to qualify for that quarter's payment.
Based on current financial metrics, JNJ's dividend appears well-covered. The EPS-based payout ratio of approximately 46%–53% is conservative for a large-cap healthcare company, providing meaningful earnings headroom above the annual dividend obligation. The primary risks are pharmaceutical patent cliffs (particularly Stelara biosimilar competition in 2025), ongoing talc litigation liability, and the potential for large acquisitions to temporarily increase leverage. J&J's 63+ year streak of consecutive increases demonstrates exceptional institutional commitment to the dividend — however, no dividend is ever guaranteed, and sustained earnings decline would eventually pressure the payout.
A Dividend Aristocrat is an S&P 500 company that has raised its dividend for at least 25 consecutive years. A Dividend King is a company — not limited to S&P 500 membership — that has raised its dividend for at least 50 consecutive years. The King designation is rarer and more stringent. JNJ qualifies for both: it is an S&P 500 member with 63+ years of consecutive increases, far exceeding both the 25-year Aristocrat threshold and the 50-year King threshold. You can view the current Dividend Aristocrat companies in our Dividend Aristocrats guide.
JNJ, Procter & Gamble (PG), and Abbott Laboratories (ABT) are all Dividend Kings with long increase streaks. PG has the longest streak (68+ years) and a similar current yield to JNJ (~2.3%–2.5%); the key difference is sector exposure (consumer staples vs. healthcare). ABT offers a higher 5-year dividend growth rate (~7%–8% CAGR) but a lower current yield (~1.7%–1.9%), making it more suitable for investors prioritizing income compounding over current cash flow. JNJ sits between the two in terms of growth rate and is preferred by investors seeking healthcare-sector dividend exposure with King-level reliability.
Yes — JNJ's quarterly dividends are generally classified as qualified dividends for U.S. individual investors who hold shares for the required period (more than 60 days during the 121-day window surrounding the ex-dividend date). Qualified dividends are taxed at the preferential long-term capital gains rate — 0%, 15%, or 20% depending on taxable income — making JNJ's dividend meaningfully more tax-efficient in a taxable brokerage account than interest-bearing investments or ordinary income dividends. Consult a qualified tax advisor for guidance specific to your situation, as individual tax circumstances vary.